Chris Waine 2026

Chris Waine

Principal Toxicologist and Director

Qualifications

MChem in Chemistry with Forensic Science

UK Registered Toxicologist (UKRT)

European Registered Toxicologist (ERT)

Chartered Chemist

Chris Waine,
Principal Toxicologist and Director

Qualifications and Experience

Chris joined bibra at the beginning of 2013 after gaining an MChem in Chemistry with Forensic Science from the University of Manchester, and has been a European Registered Toxicologist since 2018.

Chris leads on several of bibra’s projects relating to the REACH regulation, helping clients in several sectors meet their registration obligations and respond to evaluation decisions. He is also heavily involved in projects in the medicines and medical devices areas, particularly the assessment of impurities and of extractables and leachables. He is also skilled at running (Q)SAR predictions of toxicology and incorporating these results into bibra’s reports. He works closely with Leadscope on several of their working groups and is an expert panel member of the BSI and ISO Technical Committees relating to ISO 10993 on the biological evaluation of medical devices.

Areas of Expertise

Hobbies and Interests

Outside of the office, Chris enjoys a wide range of music, and can often be found at the piano or with one of his guitars. He is an avid sports fan and enjoys regular trips to visit family and friends around Europe.

Chris's case studies and blog posts

Non-clinical overview

Case study

Following the reformulation of an emollient, an increased level of an impurity was detected compared with the previous formulation. Based on this, the client proposed a new shelf-life specification limit for the impurity. Click through to read more about how we dealt with this interesting project.

A human health risk assessment of detected extractables

Case study

The client produces a foam-based drug product that patients can self-administer from an aerosol cannister. According to the manufacturer of the container-closure-system (CCS), several compounds (including some unknown constituents) were identified as extractables from two components of the cannister that directly contact the drug product.

NAMs for NGRAs

Blog articles

Traditionally, toxicological risk assessment has involved identifying a point of departure (PoD) such as a NOAEL or LOAEL in a study of small creatures, adjusting it to be relevant to humans (to derive, for example, a TI or DNEL), and then calculating the margin of safety to a measured or estimated external exposure. As part of this process, toxicologists have to account for the uncertainties that arise in moving from the species, route and duration of the laboratory animal study to the real human world.

Want to read more case studies and blog posts that Chris has been involved in? Click below to read more.

Contact us